 |
 |
 |
Answer Cancer Foundation, in collaboration with Us TOO International Prostate Cancer Education & Support Network, The Broad Institute and Dana-Farber Cancer Institute, offers a virtual presentation on the Metastatic Prostate Cancer Project. Dr. Eliezer Van Allen, the project’s Principal Investigator, introduces and explains the project with slides and responds to questions from the panel and written questions from the audience.
Panel
- Dr. Eli Van Allen, Dana Farber Cancer, Principal Investigator
- Professor Bill Burhans, Roswell Park Cancer Institute, Project Participant
- Len Sierra, Retired Research Pharmacist, Project Participant
- Jake Hannam, Project Participant
- Chuck Strand, Us TOO CEO, Co-Moderator
- Rick Davis, AnCan Founder, Co-Moderator
The MPCP is a nationwide genomic research study for men with advanced or metastatic prostate cancer. It seeks to generate the most comprehensive database to be shared with the entire research community to accelerate discoveries. MPCP focuses cutting edge genomic science squarely on people living with metastatic prostate cancer. This project was designed and has been implemented collaboratively with metastatic prostate cancer patients, patient advocates, cancer researchers, physicians, and clinical specialists.
If you are a metastatic prostate cancer patient who has not yet participated, Dr. Van Allen explains the simple process via www.mpcproject.org.
Click the PDF icon for the deck
Dr. Eliezer Van Allen is an Assistant Professor of Medicine at Harvard Medical School, a clinician at Dana-Farber/Partners Cancer Care, and an Associate Member at the Broad Institute of MIT and Harvard.
His research focuses on computational cancer genomics, the application of new technologies such as massively parallel sequencing to precision cancer medicine, and resistance to targeted therapeutics.
Originally from Los Angeles, CA, he studied at Stanford University, obtained his M.D. from UCLA, and completed a residency in internal medicine at UCSF before coming to Boston and completing a medical oncology fellowship at the Dana-Farber/Partners Cancer Care program.